Hospital Pharmacy welcomes contributions to this column, in which articles originally published in pharmacy department newsletters are reprinted. Material is selected because of its educational value or because it typifies the type of information that is interesting to pharmacy newsletter readers. If you would like us to consider your newspaper material for publication, mail a copy and a computer disk containing the document to: Hospital Pharmacy, Facts and Comparisons, 111 Westport Plaza, Suite 300, St. Louis, MO 63146.
Get full access to this article
View all access options for this article.
References
1.
GeorgeD.K., CrawfordD.G.Antibacterial-induced hepatotoxicity. Incidence, prevention, and management. Drug Saf.1996, 15(1): 79–85.
2.
McNeilJ.J., GrabschE.A., McDonaldM.M.Postmarketing surveillance strengths, and limitations. The flux-cloxacillin-dicloxacillin story. Med J Aust.1999; 170: 270–3.
3.
Personal communication. June 23, 1999. Pfizer Pty. Limited.
4.
VialT., BiourM., DescotesJ.Antibiotic-associated hepatitis: Update from 1990. Ann Pharmacother.1997;31: 204–20.
5.
RodriguezL.A.G., StrickerB.H., ZimmermanH.J.Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med.1996; 156: 1327–32.
6.
DevereauxB.M., CrawfordD.H.G., Pur-cellP.Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?Eur J Clin Pharmacol.199549: 81–5.
7.
FairleyC.K., McNeilJ.J., DesmondP.Risk factors for development of flucloxacillin associated jaundice. BMJ.1993; 306: 233–5.
